American Kidney Fund’s Local Programs Supporting Living Kidney Donors Combine to Form New Living Donor Assistance Program
January 14, 2025 12:07 ET
|
American Kidney Fund
ROCKVILLE, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) announced the consolidation of two vital initiatives—the David Atkins Fund and the living kidney donor program...
American Kidney Fund Appoints Dr. Pranav Garimella as its First Chief Medical Officer
January 08, 2025 09:01 ET
|
American Kidney Fund
ROCKVILLE, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- The American Kidney Fund today announced Dr. Pranav Garimella as its Chief Medical Officer (CMO). A nationally recognized leader in nephrology and...
Chronic Kidney Disease Market: 10-Year Growth Projections and Regional Insights
November 25, 2024 07:13 ET
|
Research and Markets
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the 68...
American Kidney Fund’s Second Patient Access Initiative Summit Will Highlight Health Care Challenges Faced by Kidney Community, Outline Public Policy Solutions
November 19, 2024 09:18 ET
|
American Kidney Fund
ROCKVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) will host its second Patient Access Initiative (PAI) Summit—part of AKF’s ongoing work to address health care...
Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission
November 15, 2024 13:15 ET
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
November 14, 2024 08:10 ET
|
ZyVersa Therapeutics
ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
October 28, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and UNI-494 – LOS ALTOS, Calif., Oct....
The American Kidney Fund Launches ‘Answers Unlocked’ Educational Campaign to Help Kidney Patients Learn About the Benefits of Genetic Testing
October 22, 2024 12:17 ET
|
American Kidney Fund
ROCKVILLE, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) launched its newest educational campaign, “Answers Unlocked,” to spread awareness of the need and benefits of...
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
October 16, 2024 16:35 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
On the Heels of Historic Hurricane Helene, American Kidney Fund Activates Disaster Relief Program to Support Dialysis and Post-Transplant Patients Affected by Hurricane Milton
October 10, 2024 13:07 ET
|
American Kidney Fund
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) has turned on its Disaster Relief Program to aid dialysis and post-transplant patients living in areas impacted by...